Vaxart, Inc. Files 8-K Report
Ticker: VXRT · Form: 8-K · Filed: Sep 19, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
Related Tickers: VXRT
TL;DR
Vaxart filed an 8-K, no major news yet.
AI Summary
On September 18, 2025, Vaxart, Inc. filed an 8-K report detailing "Other Events." The filing does not disclose specific new events, financial figures, or material changes, but rather serves as a routine update or confirmation of information.
Why It Matters
This filing indicates that Vaxart, Inc. has made a regulatory submission, which could be a precursor to future announcements or updates regarding their business operations or pipeline.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain specific negative or positive material information.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- September 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Address of principal executive office
FAQ
What is the specific nature of the 'Other Events' reported by Vaxart, Inc. on September 18, 2025?
The filing does not specify the exact nature of the 'Other Events,' as it is a general category for 8-K reports.
Does this 8-K filing disclose any new financial information or material agreements for Vaxart, Inc.?
No, this particular 8-K filing, categorized under 'Other Events,' does not disclose new financial information or material agreements.
What is the significance of Vaxart, Inc. filing an 8-K report on this date?
Filing an 8-K report signifies that Vaxart, Inc. is making a public disclosure of material information as required by the SEC, even if the specific details are not immediately apparent in the filing's summary.
What was Vaxart, Inc.'s former company name prior to 2016?
Prior to April 13, 2016, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc.
What is Vaxart, Inc.'s principal business address?
Vaxart, Inc.'s principal executive office is located at 170 Harbor Way, Suite 300, South San Francisco, California 94080.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-09-19 06:00:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT * Indicate by check
Filing Documents
- vxrt20250918d_8k.htm (8-K) — 25KB
- 0001437749-25-029434.txt ( ) — 148KB
- vxrt-20250918.xsd (EX-101.SCH) — 3KB
- vxrt-20250918_def.xml (EX-101.DEF) — 11KB
- vxrt-20250918_lab.xml (EX-101.LAB) — 14KB
- vxrt-20250918_pre.xml (EX-101.PRE) — 11KB
- vxrt20250918d_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. Vaxart, Inc. (the "Company") previously disclosed in its current report on Form 8-K, filed with the Securities and Exchange Commission (the "SEC") on September 8, 2025, that the Company convened its special meeting of stockholders (the "Special Meeting") on September 5, 2025, but adjourned the Special Meeting to provide the Company's stockholders with additional time to vote on the proposal (the "Proposal") listed in the proxy statement, which the Company filed with the SEC on August 6, 2025, for the Special Meeting. The reconvened Special Meeting was scheduled for September 19, 2025. On September 18, 2025, the Company determined to withdraw the Proposal from stockholder consideration and will not be reconvening the adjourned Special Meeting.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2025 VAXART, INC. /s/ Steven Lo Steven Lo President and Chief Executive Officer